Clinical trials: Arthroplasties, Hip Replacement
Osteoarthritis, Hip, Arthritis
A Clinical Investigation of the M2a-Magnum™ Hip System
The purpose of this prospective clinical data collection is to document the performance and clinical outcomes of the M2a-Magnum™ Hip System
- Conditions
- Osteoarthritis, Hip, Arthritis, Rheumatoid Arthritis, Joint Disease
- Trial name
- NCT00698347
- Testing
- M2a-Magnum™ Hip System
- Volunteers
- 249 people
- Sponsor
- Biomet Orthopedics, LLC
Thromboembolism, Arthroplasty, Replacement, Hip
Study to Evaluate the Safety and Efficacy of Pradaxar for the Prevention of Venous Thromboembolism in the Mexican Population Undergoing Elective Total Hip or Knee Replacement Surgery
Open, prospective, uncontrolled, observational cohort study.
- Trial name
- NCT00967447
- Where
- 28 sites in Mexico
- Volunteers
- 2 people
- Sponsor
- Boehringer Ingelheim
Arthroplasty, Replacement, Hip, Thrombosis
Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement
Patients who undergo total hip replacement surgery are at greater risk of getting deep vein thrombosis (blood clots). This study evaluates the safety, tolerability and effectiveness of the study drug, DU-176b, in reducing the…
- Trial name
- NCT00107900
- Testing
- DU-176b
- Where
- United States
- Volunteers
- 606 people
- Sponsor
- Daiichi Sankyo
Total Hip Replacement, Total Knee Replacement
An Open Label Data Collection Study of My Connect Post-Op, a Post-Operative Communication Tool
This open label, multi-center study will collect data from the participant's use of My Connect Post-Op Software as a post-operative communication solution in supporting patient recovery through Technology-Assisted Conversation…
- Trial name
- NCT07120191
- Testing
- post op communication software
- Where
- 3 sites in United States
- Volunteers
- 652 people
- Sponsor
- Concentra AI, inc
Anticoagulation
Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery
The primary purpose of this protocol is to evaluate the safety of Apixaban in prophylaxis of Venous Thromboembolism (VTE) in Indian patients undergoing elective total knee or hip replacement
- Trial name
- NCT01884337
- Testing
- Apixaban
- Where
- 20 sites in India
- Volunteers
- 557 people
- Sponsor
- Bristol-Myers Squibb
Pain, Postoperative
Safety and Efficacy Study of KAI-1678 to Treat Subjects With Postoperative Pain
The purpose of this study is to determine whether KAI-1678 is effective in the treatment of postoperative pain following total hip or total knee replacement.
- Trial name
- NCT01015235
- Testing
- KAI-1678, Ketorolac Tromethamine
- Where
- New Zealand
- Volunteers
- 90 people
- Sponsor
- KAI Pharmaceuticals
Bone Diseases, Infectious
Drug Penetration Into Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery
Debio 1450 is being developed for the treatment of staph (staphylococcal) infections. How fast and completely an antibiotic penetrates into bone is used to determine how effective it might be to treat infections related to bones…
- Trial name
- NCT02726438
- Testing
- Debio 1450
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Debiopharm International SA
Total Hip Replacement Surgery
Pharmacokinetic Study of the Penetration of Ceftobiprole in the Bone
This study is being performed to measure the amount of the antibiotic ceftobiprole (study drug) found in the bone and blood after receiving one dose prior to your elective hip replacement surgery.
- Trial name
- NCT00771524
- Testing
- Ceftobiprole
- Volunteers
- 22 people
- Sponsor
- Basilea Pharmaceutica
Venous Thromboembolism, Arthroplasty, Replacement, Hip
A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery
The purpose of this study is to evaluate the efficacy and safety of various doses of YM150 (the experimental drug) compared to enoxaparin in the prevention of venous thromboembolism in patients that are undergoing elective hip…
- Trial name
- ONYX-3 (NCT00902928)
- Testing
- YM150, enoxaparin
- Where
- 156 sites in United States, Australia and 26 more
- Volunteers
- 1,992 people
- Sponsor
- Astellas Pharma Europe B.V.
Muscular Atrophy
A Study of LY2495655 in Older Participants Undergoing Elective Total Hip Replacement
The primary objective of this study is to test the hypothesis that appendicular lean body mass (aLBM) will increase after 12 weeks of LY2495655 treatment versus placebo in older participants undergoing elective total hip…
- Trial name
- NCT01369511
- Testing
- LY2495655
- Where
- 45 sites in United States, Austria and 9 more
- Volunteers
- 400 people
- Sponsor
- Eli Lilly and Company
Hip Disease
Origin Stem and Logical Cup Post Market Clinical Follow-up
The aim of the study is to monitor the performance of the Signature Orthopaedics Origin Stem and Logical Acetabular Cup as part of post-market vigilance and continuous improvement efforts.
- Trial name
- NCT04123600
- Testing
- Origin Stem and Logical Cup
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Signature Orthopaedics
Osteoarthritis, Hip, Coxarthrosis; Primary
Osseointegration of THA Grafted by PolyNASS (ACTISURF-CERAFIT® ) Versus Non-grafted THA (CERAFIT®)
The infection rate after Total Hip Arthroplasty (THA) is about 1%. It is a serious condition, with high morbidity, sometimes fatal, requiring costly treatment.
- Conditions
- Osteoarthritis, Hip, Coxarthrosis; Primary, Coxarthrosis; Secondary, Osteonecrosis; Aseptic, Idiopathic
- Trial name
- NCT03113981
- Testing
- Total Hip Arthroplasty
- Where
- 7 sites in France
- Volunteers
- 340 people
- Sponsor
- Societe ACTIVBIOMAT
Hip Osteoarthritis
OXINIUM◊ DH Total Hip Arthroplasty Pivotal Study
The purpose of this study is to monitor safety of the participants implanted with the OXINIUM◊ DH Hip System up to 10-years post-implantation
- Trial name
- NCT02353377
- Testing
- OXINIUM DH Hip System, BIOLOX◊
- Volunteers
- 413 people
- Sponsor
- Smith & Nephew, Inc.
Arthroplasty, Replacement, Hip
A Comparative Study of In-vivo Wear Between 28 mm and 40 mm Metal Heads
Prospective, single centre, randomized clinical study; series of patients with a 5-years patient evaluation period.
- Trial name
- X3largeheads (NCT02525627)
- Testing
- Trident cup, X3 inserts, 28 mm head, Trident cup, X3 inserts, 40 mm head, Symax stem
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Stryker Orthopaedics
Deep Vein Thrombosis of Lower Limb, Pulmonary Embolism (PE)
Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)
Evaluation of the safety and effectiveness of ActiveCare+ CECT device +/- baby dose aspirin (81 mg QD) for lowering the potential risk for bleeding and of DVT during and after THA surgery in comparison with LMWH.
- Conditions
- Deep Vein Thrombosis of Lower Limb, Pulmonary Embolism (PE), Bleeding
- Trial name
- SAFE (NCT00358735)
- Testing
- ActiveCare CECT device, Enoxaparin
- Where
- 9 sites in United States
- Volunteers
- 411 people
- Sponsor
- Medical Compression Systems
Venous Thromboembolism
Dose Ranging Study in Elective Total Hip Replacement Surgery
The primary objective is to: demonstrate the efficacy of SR123781A in the prevention of venous thromboembolism (VTE) by the demonstration of a dose-response in patients undergoing total hip replacement surgery.
- Trial name
- DRIVE (NCT00338897)
- Testing
- SR123781A
- Where
- 14 sites in Argentina, Bulgaria and 12 more
- Volunteers
- 1,090 people
- Sponsor
- Sanofi
Arthroplasty, Replacement, Prevention of Venous Thromboembolism
Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
To supplement the current evidence of the effect of Pradaxa® (dabigatran etexilate) on coagulation parameters, including a calibrated thrombin time test, in patients with moderate renal impairment undergoing elective total hip…
- Conditions
- Arthroplasty, Replacement, Prevention of Venous Thromboembolism, Moderate Renal Impairment (CrCl 30-50 mL/Min)
- Trial name
- NCT01184989
- Testing
- Dabigatran etexilate
- Where
- 10 sites in Austria, Canada and 4 more
- Volunteers
- 142 people
- Sponsor
- Boehringer Ingelheim
Arthroplasty, Replacement, Hip
Tritanium® Primary Acetabular Shell Study
This study will be a prospective, non-randomized evaluation of the Tritanium® Acetabular Shell for primary total hip replacement (THR) with a cementless application in a consecutive series of patients who meet the eligibility…
- Trial name
- NCT01063751
- Testing
- Tritanium® Primary Acetabular Shell
- Where
- 7 sites in United States
- Volunteers
- 275 people
- Sponsor
- Stryker Orthopaedics
Arthroplasty, Replacement, Hip
Trident II Tritanium Acetabular Shell Outcomes Study
The purpose of this study is to review the performance and success rate of an FDA approved cementless hip replacement part called the Trident II Tritanium Acetabular Shell.
- Trial name
- NCT02999009
- Testing
- Trident II Tritanium Acetabular Shell
- Where
- 9 sites in United States
- Volunteers
- 383 people
- Sponsor
- Stryker Orthopaedics
Osteoarthritis, Rheumatoid Arthritis
A Clinical Investigation of the Taperloc® Microplasty™ Hip System
The purpose of this prospective clinical data-collection is to document the performance and clinical outcomes of the Taperloc® Microplasty™ Hip System.
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Avascular Necrosis
- Trial name
- NCT00699309
- Where
- 4 sites in United States
- Volunteers
- 98 people
- Sponsor
- Biomet Orthopedics, LLC